CuriMeta to provide privacy-protected, high-quality real-world
health data
ST.
LOUIS, March 28, 2024 /PRNewswire/ -- Verantos,
the market leader in high-validity real-world evidence (RWE) at
scale, today announced a partnership with CuriMeta that will
initially add de-identified data from 7 million patients to the
Research Network, further enhancing the breadth, depth, and
representativeness of high-quality real-world data (RWD) available
to life sciences organizations. CuriMeta's initial data
collaborators include BJC HealthCare and Washington University School of Medicine in
St. Louis.
The Verantos Research Network is a distributed collection of
academic and community health systems, claims sources, and
registries. Its focus on high-quality data ensures that customers
have access to RWD with unparalleled richness and reliability.
"The Verantos Evidence Platform uses artificial intelligence
(AI) to generate unique disease-specific insights. It is critical
that AI models are trained using high-quality patient care data,"
said Anand Shroff, President of
Verantos. "CuriMeta's participation will enable us to enhance our
disease-specific Pragmatic Registries that are used to accelerate
life sciences research."
CuriMeta's mission is to connect leading, mission-driven health
systems and academic medical centers with life sciences
organizations to pursue ground-breaking research and deliver new
diagnostics and therapeutics, and the collaboration with the
Verantos Research Network helps further those goals.
"Complex therapies necessitate providing more robust evidence
and greater clinical value to achieve acceptance by regulators,
providers, and patients," Davis
Walp, CEO of CuriMeta, said. "Our partnership with Verantos
will help connect patients with lifesaving therapies in the
future."
The two companies will collaborate across therapeutic areas.
CuriMeta's data will support a number of Verantos' current and
planned disease-specific Pragmatic Registries.
About Verantos
Verantos is the global leader in high-validity real-world evidence
at scale. By applying artificial intelligence to the complete
patient record, Verantos enables life sciences organizations to
generate high-validity evidence across therapeutic areas with
measured accuracy, completeness, and traceability. Credible
evidence accelerates clinical development, market access, medical
affairs, pharmacovigilance, and regulatory initiatives.
About CuriMeta
In collaboration with leading health systems and academic medical
centers, CuriMeta transforms, curates, and enables researchers'
access to multi-modal real-world health data to provide the
insights required to solve urgent scientific and clinical
challenges, and improve healthcare for all. The highly experienced
and scientifically focused team at CuriMeta are committed to
propelling health science forward and improving patient outcomes
across all therapeutic areas. For more information on how to
partner with CuriMeta on your research portfolio,
visit CuriMeta.com.
Media Contacts
Verantos:
PRforVerantos@bospar.com
CuriMeta: jgordon@spectrumscience.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/verantos-announces-partnership-with-curimeta-to-advance-high-validity-real-world-evidence-302101784.html
SOURCE CuriMeta; Verantos